Brought to you by 
AZ completes Entocort divestiture; grants Perrigo rights in US
25 Sep 2017
Executive Summary
AstraZeneca PLC granted Perrigo Co. PLC exclusive rights to sell its Crohn's disease therapy Entocort (budesonide) in the US. The transaction completes AZ's strategic divestiture of the product; Tillotts Pharma got global rights (excluding the US) in July.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ completes Entocort divestiture; grants Perrigo rights in US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice